Concepedia

John E. Linnehan

JE

Statistics

Publications

4

Citations

301

H-Index

4

Active since

2006

Affiliations

Janssen (Belgium)(Current)

John E. Linnehan is an author at Janssen (Belgium) specializing in pharmacoeconomics, cost-effectiveness analysis, and pharmacoeconomic modeling.

Publications per year

2006–2013

4

Publications

4

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective

Stuart Connolly, Siyang Peng, John E. Linnehan et al. · Thrombosis and Haemostasis · 2011 · 204 citations

Medicine, Pharmacoeconomics, Pharmacotherapy +17

Histidines 13 and 14 in the Aβ sequence are targets for inhibition of Alzheimer's disease Aβ ion channel and cytotoxicity

Juan Carlos Díaz, John E. Linnehan, Harvey B. Pollard et al. · Biological Research · 2006 · 38 citations · Full text

Life Sciences, Biochemistry, Neuroscience +17

Economic Analysis of Decitabine Versus Best Supportive Care in the Treatment of Intermediate- and High-Risk Myelodysplastic Syndromes From a US Payer Perspective

Feng Pan, Siyang Peng, Rachael Fleurence et al. · Clinical Therapeutics · 2010 · 31 citations

Pharmacy, Internal Medicine, Pharmacoeconomics +10

Budgetary Impact on a U.S. Health Plan Adopting Abiraterone Acetate Plus Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer

Sonja Sorensen, Lorie Ellis, Ying Wu et al. · Journal of Managed Care Pharmacy · 2013 · 28 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17

1–4 of 4